Evidence map›Paper›PMID 41509083›Full record

ArticleClinical case reports2026

Delayed Aggressive Local Recurrence of Chondroblastic Osteosarcoma 3 Years After an Excellent Pathological Response: A Case Report.

Abdul Hannan, Bilal Aslam, Natasha Hastings, Deepa Lachhman Das, Zahra Sania, Marium Mansoor, Fazeela Bibi, Khalil El Abdi, Samreen Najeeb, Kristen Batten and 2 more

Abstract read
In one paragraph

Article in Clinical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Abdul HannanUniversity College of Medicine and Dentistry University of Lahore Lahore Pakistan.
Bilal AslamUniversity College of Medicine and Dentistry University of Lahore Lahore Pakistan.
Natasha HastingsSchool of Medicine St. George's University St. George Grenada.
Deepa Lachhman DasIndus Medical College Tando Muhammad Khan Pakistan.
Zahra SaniaWomen Medical and Dental College Khyber Medical University Peshawar Pakistan.
Marium MansoorFatima Jinnah Medical University Lahore Pakistan.
Fazeela BibiJinnah Medical and Dental College Kirachi Pakistan.
Khalil El AbdiFaculty of Medicine and Pharmacy of Rabat Mohammed V University Rabat Morocco.
Samreen NajeebWomen Medical and Dental College Khyber Medical University Peshawar Pakistan.
Kristen BattenSt. James School of Medicine Park Ridge Illinois USA.
Manisha KumariIndus Medical College Tando Muhammad Khan Pakistan.
Said Hamid SadatKabul University of Medical Sciences Kabul Afghanistan.ORCID https://orcid.org/0009-0006-7885-6214

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Late recurrence of osteosarcoma after a prolonged disease-free interval is an uncommon but significant clinical challenge, representing a failure of primary therapy to eradicate microscopic residual disease. We present the case of a 19-year-old male diagnosed with chondroblastic osteosarcoma of the proximal tibia who was treated with standard multimodal therapy, including neoadjuvant chemotherapy and limb-salvage surgery. He achieved wide (R0) surgical margins and an excellent (Huvos Grade IV, > 95% necrosis) pathological response. After a 3-year disease-free interval, he presented with an aggressive and extensive local recurrence in the residual tibia, which ultimately necessitated a below-knee amputation for local control. This case demonstrates that an excellent initial pathological response and wide surgical margins do not preclude the risk of a delayed and highly aggressive relapse in osteosarcoma. It serves as a critical reminder that a "cure" is provisional and underscores the absolute necessity of indefinite, long-term oncologic surveillance for all survivors. The phenomenon of late recurrence highlights the urgent need for research into tumor dormancy and the development of surveillance tools capable of detecting minimal residual disease.

Indexed as

late relapselocal recurrenceoncologic surveillanceosteosarcomatumor dormancy

Identifiers

PMID41509083
PMCPMC12778439

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.